Pharmacia & Upjohn epirubicin
Executive Summary
FDA's Oncologic Drugs Advisory Committee will meet on the afternoon of June 7 to discuss epirubicin as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of stage II or stage III breast cancer. The morning session will convene at 10:30 a.m. to discuss use of time to progression as a primary endpoint in Phase III breast cancer trials